We appreciate Ward and colleagues' interest in our work [1] and the opportunity to respond. We confirm that the spina bifida cases we reviewed are carriers of the R46L variant minor allele. As acknowledged in our paper, both the size of our observed spectrum of p values and the limited spectrum of PCSK9 variants in our existing genotyping platform suggest our data may be underpowered for fully understanding the connections identified. We note that the most conservative Bonferroni correction for multiplicity in this dataset would be approximately 6 × 10 −6 , and the authors are correct that our association with neural tube defects is below this threshold. The association with a diagnosis of hypercholesterolemia, a known association with the R46L variant, is also below the threshold. However, the existence of animal and human data suggestive of a potential link between PCSK9 and spina bifida, in concordance with the association we observed, suggests prudence in safety signal reporting is warranted. As described in our paper, decreased PCSK9 was found in both a rat fetal model of neural tube defects and women carrying a fetus affected by a neural tube defect, with PCSK9 level additionally noted to be a potentially useful biomarker in humans, with sensitivity of 57% and specificity of 98% [2] . Furthermore, the UK Biobank is an epidemiologic cohort of middle-aged subjects and thus may underrepresent phenotypes such as spina bifida seen primarily in younger patients.
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